Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1645 1652 1656
This examiner grants 82% of resolved cases
Examiner Christian L Fronda works in Tech Center 1600 and Art Unit 1645. There are 1361 resolved cases with an allowance rate of 82.4 percent. This percentage provides a metric for the probability of a grant. The median days to allowance is 886. This timeframe is a factor in managing patent applications for clients.
The interview lift is 14.2 percent. For the 1361 resolved cases, this lift shows the correlation between interviews and outcomes. The 886 days to allowance serves as a benchmark for pendency. Practitioners can use the 82.4 percent allowance rate and the Art Unit 1645 data to inform strategy for their applications. These metrics from Tech Center 1600 assist in prosecution planning for the office.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18037996 | SHEWANELLA ONEIDENSIS-DERIVED PROTEIN EXPRESSING MICROORGANISM AND L-AMINO ACID PRODUCING METHOD USING SAME | Non-Final OA | CJ CHEILJEDANG CORPORATION |
| 19578476 | R-BUTYLENE GLYCOL TOPICAL COMPOSITIONS FOR ANTI-AGING, SKIN PROTECTION AND HAIR TREATMENT | Non-Final OA | KetoneAid, Inc. |
| 18678629 | EXOGENOUS KETONE BLEND COMPOSITIONS FOR DELIVERY OF KETONE BODIES | Final Rejection | KetoneAid, Inc. |
| 18398165 | Nucleic Acid Synthesis and Sequencing Using Tethered Nucleoside Triphosphates | Final Rejection | The Regents of the University of California |
| 18277444 | ARTIFICIAL DNA REPLISOME AND METHODS OF USE THEREOF | Non-Final OA | Regents of the University of Minnesota |
| 18886300 | PLATFORM OF COMPOSABLE MAMMALIAN ELEMENTS OF TRANSCRIPTION (COMET) | Non-Final OA | Northwestern University |
| 18553817 | ENZYME COMPOSITION | Non-Final OA | DSM IP Assets B.V. |
| 18847406 | ALPHA-AMYLASE VARIANT | Non-Final OA | KAO CORPORATION |
| 19019935 | PROCESSES FOR PRODUCING ETHANOL | Non-Final OA | NOVOZYMES A/S |
| 18956701 | POLYPEPTIDES HAVING LYSOZYME ACTIVITY, POLYNUCLEOTIDES ENCODING SAME AND USES AND COMPOSITIONS THEREOF | Non-Final OA | Novozymes A/S |
| 18896095 | STABILIZED CELLULASE VARIANTS | Non-Final OA | Novozymes A/S |
| 18578592 | RECOMBINANT YEAST CELL | Final Rejection | DANISCO US INC. |
| 18297346 | GENE EDITING COMPONENTS, SYSTEMS, AND METHODS OF USE | Final Rejection | ReNAgade Therapeutics Management Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy